Xspray Pharma AB (XSPRAY) Stock Statistics & Valuation Metrics

Xspray Pharma AB has a market cap or net worth of €1.04B. The enterprise value is kr1.88B.

Xspray Pharma AB has 41,742,340 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xspray Pharma AB’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -37.68%.

The current PE Ratio of Xspray Pharma AB is ―. Xspray Pharma AB’s PEG ratio is -0.17.

In the last 12 months, Xspray Pharma AB had revenue of 0.00 and earned -285.52M in profits. Earnings per share was -8.62.

In the last 12 months, operating cash flow was -213.39M and capital expenditures -40.03M, giving a free cash flow of -253.43M billion.

Xspray Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Xspray Pharma AB upcoming earnings date is Feb 18, 2026, Before Open (Confirmed).

Xspray Pharma AB as a current ratio of 1.61, with Debt / Equity ratio of 23.21%

In the past 12 months, Xspray Pharma AB has paid -151.00K in taxes.

Xspray Pharma AB EV to EBITDA ratio is -4.65, with an EV/FCF ratio of -4.89.

Xspray Pharma AB has €197.98M in cash and marketable securities with €148.91M in debt, giving a net cash position of €49.07M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Xspray Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―